calcyclin binding protein pseudogene 1Genealiases: []
Q-omics provides the consensus-scored CACYBPP1 profile across patient tissues and cancer cell-line models. CACYBPP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CACYBPP1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, CACYBPP1 RNA expression shows 10,592 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where CACYBPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACYBPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACYBPP1 survival associations across molecular data types. CACYBPP1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACYBPP1 RNA expression–survival associations across cancer types. High CACYBPP1 expression shows unfavorable associations in KIRC, UVM, LIHC and PCPG, but favorable associations in PAAD and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CACYBPP1 RNA expression.
This table summarizes CACYBPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CACYBPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACYBPP1 shows lower tumor expression in HNSC, LIHC, LUSC and THCA. The HNSC box plot shows higher CACYBPP1 RNA expression in normal versus tumor tissue (log2 FC = −0.046, t-test p = .026).
This table shows molecular features associated with CACYBPP1 in patient tissues and cancer cell lines. In patient samples, CACYBPP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
